FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379662280> ?p ?o ?g. }

• W4379662280 endingPage "LBA637" @default.
• W4379662280 startingPage "LBA637" @default.
• W4379662280 abstract "LBA637 Background: The ShortHER trial is a phase III non-inferiority, randomized trial comparing 9 weeks (short arm) versus 1 year (long arm) of adjuvant trastuzumab combined with chemotherapy in HER2+ eBC patients. The first primary end point of the study was the event-driven analysis of disease-free survival which was achieved in 2017, presented at ASCO 2017 and published in Annals of Oncology in 2018. The HR was 1.13 (90% CI 0.89-1.42) and the non-inferiority could not be claimed as the upper border of CI crossed the upper limit of 1.29 chosen as non-inferiority margin. According to a pre-planned Bayesian analysis, the probability that the short arm was not inferior to the standard one was 80%. Methods: 1254 HER2+ early breast cancer patients were stratified according to nodal status and randomized. Median age was 55 years (range 25-78); 672 (54%) patients were node negative, 383 (30%) with 1-3 positive nodes, 198 (16%) 4 or more positive nodes. At the time of the event-driven analysis, median follow up was 6 years, 200 DFS events and 78 deaths were reported. Here we report the overall survival,+ which was the second co-primary end point, updated DFS and outcomes according to nodal status. Results: Median follow-up is now 9 years, 248 DFS events and 116 deaths have been reported. The 10 year DFS is 77% in the long arm and 78% in the short arm (HR 1.06; 90% CI 0.86-1.31). The 10-year OS is 89% in the long arm and 88% in the short arm (HR 1.15; 90% CI 0.85-1.56). The DFS and OS data overall and by nodal status are summarized in the table below. Conclusions: At a median follow-up of 9 years, the ShortHER trial shows that 1 year trastuzumab is still the standard treatment for HER2+ eBC patients as non-inferiority cannot be claimed in terms of DFS or OS. Numerically however, the differences for the patients at low risk (N0) or intermediate risk (N 1-3) is negligible and patients with 4 or more positive lymph nodes have a clear benefit with 1 year trastuzumab. I. This long-term date can reassure clinicians if, for any reason a patient at low/intermediate risk has to stop trastuzumab and, more important, might facilitate access to a far less expensive treatment to the thousands of patients worldwide who cannot afford the cost of one year of trastuzumab. Clinical trial information: NCT00629278 . [Table: see text]" @default.
• W4379662280 created "2023-06-08" @default.
• W4379662280 creator A5000297270 @default.
• W4379662280 creator A5002166114 @default.
• W4379662280 creator A5004001131 @default.
• W4379662280 creator A5011936352 @default.
• W4379662280 creator A5013748999 @default.
• W4379662280 creator A5016597149 @default.
• W4379662280 creator A5018395267 @default.
• W4379662280 creator A5033429638 @default.
• W4379662280 creator A5034632931 @default.
• W4379662280 creator A5037416860 @default.
• W4379662280 creator A5043754635 @default.
• W4379662280 creator A5045238785 @default.
• W4379662280 creator A5048969389 @default.
• W4379662280 creator A5051936901 @default.
• W4379662280 creator A5061442440 @default.
• W4379662280 creator A5063676677 @default.
• W4379662280 creator A5068906915 @default.
• W4379662280 creator A5070419785 @default.
• W4379662280 creator A5076498258 @default.
• W4379662280 creator A5077829056 @default.
• W4379662280 date "2023-06-10" @default.
• W4379662280 modified "2023-09-26" @default.
• W4379662280 title "Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial." @default.
• W4379662280 doi "https://doi.org/10.1200/jco.2023.41.17_suppl.lba637" @default.
• W4379662280 hasPublicationYear "2023" @default.
• W4379662280 type Work @default.
• W4379662280 citedByCount "0" @default.
• W4379662280 crossrefType "journal-article" @default.
• W4379662280 hasAuthorship W4379662280A5000297270 @default.
• W4379662280 hasAuthorship W4379662280A5002166114 @default.
• W4379662280 hasAuthorship W4379662280A5004001131 @default.
• W4379662280 hasAuthorship W4379662280A5011936352 @default.
• W4379662280 hasAuthorship W4379662280A5013748999 @default.
• W4379662280 hasAuthorship W4379662280A5016597149 @default.
• W4379662280 hasAuthorship W4379662280A5018395267 @default.
• W4379662280 hasAuthorship W4379662280A5033429638 @default.
• W4379662280 hasAuthorship W4379662280A5034632931 @default.
• W4379662280 hasAuthorship W4379662280A5037416860 @default.
• W4379662280 hasAuthorship W4379662280A5043754635 @default.
• W4379662280 hasAuthorship W4379662280A5045238785 @default.
• W4379662280 hasAuthorship W4379662280A5048969389 @default.
• W4379662280 hasAuthorship W4379662280A5051936901 @default.
• W4379662280 hasAuthorship W4379662280A5061442440 @default.
• W4379662280 hasAuthorship W4379662280A5063676677 @default.
• W4379662280 hasAuthorship W4379662280A5068906915 @default.
• W4379662280 hasAuthorship W4379662280A5070419785 @default.
• W4379662280 hasAuthorship W4379662280A5076498258 @default.
• W4379662280 hasAuthorship W4379662280A5077829056 @default.
• W4379662280 hasConcept C121608353 @default.
• W4379662280 hasConcept C126322002 @default.
• W4379662280 hasConcept C141071460 @default.
• W4379662280 hasConcept C143998085 @default.
• W4379662280 hasConcept C146357865 @default.
• W4379662280 hasConcept C151730666 @default.
• W4379662280 hasConcept C168563851 @default.
• W4379662280 hasConcept C203092338 @default.
• W4379662280 hasConcept C207103383 @default.
• W4379662280 hasConcept C2779786085 @default.
• W4379662280 hasConcept C44249647 @default.
• W4379662280 hasConcept C530470458 @default.
• W4379662280 hasConcept C71924100 @default.
• W4379662280 hasConcept C86803240 @default.
• W4379662280 hasConceptScore W4379662280C121608353 @default.
• W4379662280 hasConceptScore W4379662280C126322002 @default.
• W4379662280 hasConceptScore W4379662280C141071460 @default.
• W4379662280 hasConceptScore W4379662280C143998085 @default.
• W4379662280 hasConceptScore W4379662280C146357865 @default.
• W4379662280 hasConceptScore W4379662280C151730666 @default.
• W4379662280 hasConceptScore W4379662280C168563851 @default.
• W4379662280 hasConceptScore W4379662280C203092338 @default.
• W4379662280 hasConceptScore W4379662280C207103383 @default.
• W4379662280 hasConceptScore W4379662280C2779786085 @default.
• W4379662280 hasConceptScore W4379662280C44249647 @default.
• W4379662280 hasConceptScore W4379662280C530470458 @default.
• W4379662280 hasConceptScore W4379662280C71924100 @default.
• W4379662280 hasConceptScore W4379662280C86803240 @default.
• W4379662280 hasIssue "17_suppl" @default.
• W4379662280 hasLocation W43796622801 @default.
• W4379662280 hasOpenAccess W4379662280 @default.
• W4379662280 hasPrimaryLocation W43796622801 @default.
• W4379662280 hasRelatedWork W1722328147 @default.
• W4379662280 hasRelatedWork W2066747782 @default.
• W4379662280 hasRelatedWork W2560406314 @default.
• W4379662280 hasRelatedWork W2627001382 @default.
• W4379662280 hasRelatedWork W2751941543 @default.
• W4379662280 hasRelatedWork W2896532861 @default.
• W4379662280 hasRelatedWork W2934076975 @default.
• W4379662280 hasRelatedWork W4242374293 @default.
• W4379662280 hasRelatedWork W4322771458 @default.
• W4379662280 hasRelatedWork W2342209702 @default.
• W4379662280 hasVolume "41" @default.
• W4379662280 isParatext "false" @default.
• W4379662280 isRetracted "false" @default.
• W4379662280 workType "article" @default.